Nisin dosing & administration
FDA GRAS-approved lantibiotic (34 amino acids) produced by Lactococcus lactis with a dual antimicrobial mechanism — binds lipid II to block cell wall synthesis AND forms 2 nm transmembrane pores for rapid bacterial killing at MIC 0.5-4 μg/mL against gram-positive pathogens including MRSA and Listeria monocytogenes — the only antimicrobial peptide with over 50 years of documented safe human consumption
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Topical: Applied onto the skin as a cream, gel, or lotion — it works mainly where you put it.
Bioavailability Local — acts mainly at the skin; little reaches the bloodstream.
10-50 mcg/mL applied to the affected area
Frequency
Once or twice daily
Duration
Research protocol-dependent (typically 1-4 weeks)
Topical antimicrobial concentration range used in wound-care and infection-control research [5]. Investigational; not an approved human therapeutic route.
Timing
Best time to take
Take Nisin at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Nisin can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Nisin should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Nisin is administered Oral (food-grade preservative, GRAS)—no injection required
Best sites
Storage
Before reconstitution
Store Nisin in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Nisin should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Oral (food-grade preservative, GRAS)—rotate sites if applicable
Maintain a consistent schedule for optimal results with Nisin. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: No significant effects at dietary levels, Mild GI discomfort at research doses, Local irritation (topical use)
Less common: Milk protein allergic reaction, Gram-negative overgrowth
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Nisin
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Nisin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Alkaline formulations (pH >7) — nisin activity and stability decrease significantly above neutral pH, with degradation accelerating at alkaline conditions — Use with caution—discuss with your healthcare provider.
- Proteolytic enzymes (trypsin, chymotrypsin at high concentrations) — while lanthionine bridges provide some resistance, extensive proteolysis can reduce activity — Use with caution—discuss with your healthcare provider.
- High-fat food matrices without emulsification — nisin may partition into fat phase, reducing aqueous concentration and antimicrobial activity — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
't Hart P, Oppedijk SF, Breukink E, et al. · 2016
Nisin binds to bacterial lipid II through its pyrophosphate group, with the complete sugar unit required for tight binding and pore formation in bacterial membranes.
Ahmadi S, Ghollasi M, Hosseini HM · 2017
Research (2016) on nisin contributes important scientific knowledge about its biological and pharmacological properties.
Joo NE, Ritchie K, Kamarajan P, Miao D, Kapila YL · 2012
Study (2012) characterizes the biological activity and functional properties of nisin.
Al-Khazaleh AK, Alsherbiny MA, Chang D, et al. · 2025
Study (2014) elucidates the molecular mechanism of action and biological pathways by which nisin produces therapeutic effects.
Jesus C, Soares R, Cunha E, Grilo M, Tavares L, Oliveira M · 2021
In vitro study of nisin (as a nisin-biogel) against Staphylococcus aureus isolated from diabetic foot wound infections. The mean nisin MIC against these wound isolates was approximately 22.5 ug/mL, with sub-inhibitory concentrations (~2.8-11.25 ug/mL) tested for effects on virulence-gene expression. This supports the ~10-50 ug/mL range used in topical/wound antimicrobial formulation work; it is in-vitro/formulation research, not an approved human therapeutic dose.
Head to head
Nisin compared
Want the full picture?
The complete Nisin research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.